BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

369.06 5.02 −1.34%
Market cap
$39.0B
P/E
62.6×
Fwd P/E
40.2×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
48.30 63.86 116.40 587.41

+8 more quarters

P/S ratio
5.19 5.74 6.20 7.55
P/FCF ratio
24.27 30.10 35.95 71.58
P/Operating CF
68.70 163.66 79.39 93.28
P/B ratio
6.15 6.92 7.60 9.09
EV/Sales
4.55 5.13 5.59 6.83
EV/EBITDA
25.89 35.23 50.74 100.35
EV/FCF
21.30 26.91 32.41 64.78
Current Ratio
3.41 3.64 3.41 2.39
Net Debt/EBITDA
(11.53) (13.16) (16.22) (19.45)
Debt/Equity
0.17 0.20 0.22 0.03
Earnings Yield
2.07% 1.57% 0.86% 0.17%
Free Cash Flow Yield
4.12% 3.32% 2.78% 1.40%
Free Cash Flow per Share
3.90 1.45 3.48 3.22
Book value per Share
46.37 42.90 39.99 37.47
Free Cash Flow
435.34 160.55 379.83 354.47
EV/EBIT
30.23 42.94 66.82 186.02
Other line items

Show all line items

Columns are period end dates